Aptorum Group Limited (NASDAQ: APM)
$1.1900
-0.0400 ( -5.56% ) 52.7K
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
Market Data
Open
$1.1900
Previous close
$1.2300
Volume
52.7K
Market cap
$8.43M
Day range
$1.1600 - $1.2900
52 week range
$0.4600 - $17.4900
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| s-8 | Registration statements | 6 | Jul 26, 2024 |
| 6-k | Form 6-K | 2 | May 31, 2024 |
| 20-f | Annual reports | 126 | Apr 30, 2024 |
| 6-k | Form 6-K | 3 | Apr 30, 2024 |
| sc | Insider transactions | 1 | Apr 16, 2024 |
| 6-k | Form 6-K | 6 | Mar 06, 2024 |
| sc | Insider transactions | 2 | Feb 02, 2024 |